Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Imaging of metastatic lymph nodes by X-ray phase-contrast micro-tomography.

Jensen TH, Bech M, Binderup T, Böttiger A, David C, Weitkamp T, Zanette I, Reznikova E, Mohr J, Rank F, Feidenhans'l R, Kjær A, Højgaard L, Pfeiffer F.

PLoS One. 2013;8(1):e54047. doi: 10.1371/journal.pone.0054047. Epub 2013 Jan 18.

2.

Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity.

Kim J, Villadsen R, Sørlie T, Fogh L, Grønlund SZ, Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H, Edwards PA, Børresen-Dale AL, Rønnov-Jessen L, Bissell MJ, Petersen OW.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6124-9. doi: 10.1073/pnas.1203203109. Epub 2012 Mar 27.

3.

Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE.

Mol Oncol. 2010 Dec;4(6):539-61. doi: 10.1016/j.molonc.2010.09.005. Epub 2010 Oct 8.

4.

Quality indicators in breast cancer care.

Del Turco MR, Ponti A, Bick U, Biganzoli L, Cserni G, Cutuli B, Decker T, Dietel M, Gentilini O, Kuehn T, Mano MP, Mantellini P, Marotti L, Poortmans P, Rank F, Roe H, Scaffidi E, van der Hage JA, Viale G, Wells C, Welnicka-Jaskiewicz M, Wengstöm Y, Cataliotti L.

Eur J Cancer. 2010 Sep;46(13):2344-56. doi: 10.1016/j.ejca.2010.06.119. Epub 2010 Jul 31.

PMID:
20675120
5.

Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker.

Gromov P, Gromova I, Friis E, Timmermans-Wielenga V, Rank F, Simon R, Sauter G, Moreira JM.

J Proteome Res. 2010 Aug 6;9(8):3941-53. doi: 10.1021/pr100160u.

PMID:
20527979
6.

Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment.

de Neergaard M, Kim J, Villadsen R, Fridriksdottir AJ, Rank F, Timmermans-Wielenga V, Langerød A, Børresen-Dale AL, Petersen OW, Rønnov-Jessen L.

Am J Pathol. 2010 Mar;176(3):1229-40. doi: 10.2353/ajpath.2010.090648. Epub 2010 Feb 4.

7.

Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE.

Mol Oncol. 2010 Feb;4(1):65-89. doi: 10.1016/j.molonc.2009.11.003. Epub 2009 Nov 23.

8.

DNA copy number aberrations in breast cancer by array comparative genomic hybridization.

Li J, Wang K, Li S, Timmermans-Wielenga V, Rank F, Wiuf C, Zhang X, Yang H, Bolund L.

Genomics Proteomics Bioinformatics. 2009 Jun;7(1-2):13-24. doi: 10.1016/S1672-0229(08)60029-7.

9.

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.

Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, Mouridsen HT; Danish Breast Cancer Cooperative Group.

J Natl Cancer Inst. 2009 May 20;101(10):729-35. doi: 10.1093/jnci/djp090. Epub 2009 May 12.

PMID:
19436035
10.

Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F.

Mol Oncol. 2009 Jun;3(3):220-37. doi: 10.1016/j.molonc.2009.01.005. Epub 2009 Feb 3.

11.

A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Gromov P, Celis JE, Gromova I, Rank F, Timmermans-Wielenga V, Moreira JM.

Mol Oncol. 2008 Dec;2(4):368-79. doi: 10.1016/j.molonc.2008.09.003. Epub 2008 Oct 2.

12.

Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.

Li J, Gromov P, Gromova I, Moreira JM, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L, Celis JE.

Proteomics. 2008 Dec;8(23-24):5038-52. doi: 10.1002/pmic.200800303.

PMID:
19003862
13.

Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.

Nielsen BS, Egeblad M, Rank F, Askautrud HA, Pennington CJ, Pedersen TX, Christensen IJ, Edwards DR, Werb Z, Lund LR.

PLoS One. 2008 Aug 13;3(8):e2959. doi: 10.1371/journal.pone.0002959.

14.

15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.

Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I.

Mol Cell Proteomics. 2008 Oct;7(10):1795-809. doi: 10.1074/mcp.R800011-MCP200. Epub 2008 Jul 16.

15.
16.

Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol.

Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, Mouridsen HT.

Acta Oncol. 2008;47(4):672-81. doi: 10.1080/02841860801971439.

PMID:
18465335
17.

Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.

Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM.

Mol Oncol. 2007 Dec;1(3):321-49. doi: 10.1016/j.molonc.2007.09.004. Epub 2007 Sep 25.

18.

Immunohistochemical staining for thyroid peroxidase (TPO) of needle core biopsies in the diagnosis of scintigraphically cold thyroid nodules.

Yousaf U, Christensen LH, Rasmussen AK, Jensen F, Mollerup CL, Kirkegaard J, Lausen I, Rank F, Feldt-Rasmussen U.

Clin Endocrinol (Oxf). 2008 Jun;68(6):996-1001. Epub 2007 Nov 19.

19.

[Preoperative biopsy diagnosis in suspicion of breast cancer].

Rasmussen BB, Bak M, Rank FE.

Ugeskr Laeger. 2007 Sep 3;169(36):2985-7. Danish.

PMID:
17953876
20.

[Carcinoma in situ of the breast].

Laenkholm AV, Hoffmann J, Rank FE.

Ugeskr Laeger. 2007 Sep 10;169(37):3087-90. Danish.

PMID:
17877955
21.

Invasive lobular breast cancer. Prognostic significance of histological malignancy grading.

Talman ML, Jensen MB, Rank F.

Acta Oncol. 2007;46(6):803-9.

PMID:
17653904
22.

Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival.

Grabau D, Jensen MB, Rank F, Blichert-Toft M.

APMIS. 2007 Jul;115(7):828-37.

PMID:
17614850
23.

Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.

Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N.

Int J Cancer. 2007 Oct 1;121(7):1433-44.

24.

Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F.

Mol Oncol. 2007 Jun;1(1):97-119. doi: 10.1016/j.molonc.2007.02.005. Epub 2007 Mar 14.

25.

Evidence for a stem cell hierarchy in the adult human breast.

Villadsen R, Fridriksdottir AJ, Rønnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, Bissell MJ, Petersen OW.

J Cell Biol. 2007 Apr 9;177(1):87-101.

26.
27.

Performance of combined clinical mammography and needle biopsy: a nationwide study from Denmark.

Jensen A, Rank F, Dyreborg U, Severinsen N, Nielsen S, Lynge E, Vejborg I.

APMIS. 2006 Dec;114(12):884-92.

PMID:
17207089
28.

Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.

Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F.

FEBS Lett. 2006 May 22;580(12):2935-44. Epub 2006 Apr 12. Review.

29.

Performance of clinical mammography: a nationwide study from Denmark.

Jensen A, Vejborg I, Severinsen N, Nielsen S, Rank F, Mikkelsen GJ, Hilden J, Vistisen D, Dyreborg U, Lynge E.

Int J Cancer. 2006 Jul 1;119(1):183-91.

30.

Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.

Celis JE, Gromov P, Moreira JM, Cabezón T, Friis E, Vejborg IM, Proess G, Rank F, Gromova I.

Mol Cell Proteomics. 2006 Mar;5(3):462-83. Epub 2005 Nov 28.

31.

Managing compliance in production-insights and comparisons in chemical-pharmaceutical companies.

Rank F, Scheuermann HJ, Wozniewski T, Müller RH.

PDA J Pharm Sci Technol. 2005 Jul-Aug;59(4):233-9. No abstract available.

PMID:
16218201
32.

Radiation doses to staff involved in sentinel node operations for breast cancer.

Klausen TL, Chakera AH, Friis E, Rank F, Hesse B, Holm S.

Clin Physiol Funct Imaging. 2005 Jul;25(4):196-202.

PMID:
15972020
33.

A role for ADAM12 in breast tumor progression and stromal cell apoptosis.

Kveiborg M, Fröhlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P, Kronqvist P, Rank F, Mercurio AM, Wewer UM.

Cancer Res. 2005 Jun 1;65(11):4754-61.

34.

Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy--a prospective observational study.

Stahlberg C, Lynge E, Andersen ZJ, Keiding N, Ottesen B, Rank F, Hundrup YA, Obel EB, Pedersen AT.

Int J Epidemiol. 2005 Aug;34(4):931-5. Epub 2005 May 24. No abstract available.

PMID:
15914504
35.

A model for determining the effect of mammography service screening.

Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E.

Acta Oncol. 2005;44(2):120-8.

PMID:
15788290
37.
38.

Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.

Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E.

BMJ. 2005 Jan 29;330(7485):220. Epub 2005 Jan 13.

39.

Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast.

Moreira JM, Ohlsson G, Rank FE, Celis JE.

Mol Cell Proteomics. 2005 Apr;4(4):555-69. Epub 2005 Jan 11.

40.

Towards discovery-driven translational research in breast cancer.

Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P.

FEBS J. 2005 Jan;272(1):2-15. Review.

41.

Improving the reproducibility of diagnosing micrometastases and isolated tumor cells.

Cserni G, Bianchi S, Boecker W, Decker T, Lacerda M, Rank F, Wells CA; European Working Group for Breast Screening Pathology.

Cancer. 2005 Jan 15;103(2):358-67.

42.

Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.

Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E.

Br J Cancer. 2004 Aug 16;91(4):644-50.

43.

Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study.

Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Connolly CE, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Peterse JL, Rank F, Reiner A, Saksela E, Sigal-Zafrani B, Sylvan M, Borisch B, Cserni G, Decker T, Kerner H, Kulka J, Regitnig P, Sapino A, Tanous AM, Thorstenson S, Zozaya E; European Working Group for Breast Screening Pathology.

Virchows Arch. 2004 Aug;445(2):119-28. Epub 2004 Jun 24.

PMID:
15221370
44.

Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology.

Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Borisch B, Connolly CE, Decker T, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafrani B, Tanous AM, Thorstenson S, Zozaya E, Fejes G, Wells CA.

J Clin Pathol. 2004 Jul;57(7):695-701.

45.

Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.

Celis JE, Gromov P, Cabezón T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I.

Mol Cell Proteomics. 2004 Apr;3(4):327-44. Epub 2004 Jan 30.

46.

A comparison of reproductive risk factors for CIS lesions and invasive breast cancer.

Wohlfahrt J, Rank F, Kroman N, Melbye M.

Int J Cancer. 2004 Feb 20;108(5):750-3.

47.

The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Offersen BV, Nielsen BS, Høyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, Andreasen PA.

Am J Pathol. 2003 Nov;163(5):1887-99.

48.

Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines.

Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Bussolati G, Boecker W, Borisch B, Connolly CE, Decker T, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafrani B, Tanous AM, Thorstenson S, Zozaya E, Wells CA; European Working Group for Breast Screening Pathology.

Eur J Cancer. 2003 Aug;39(12):1654-67. Review.

PMID:
12888359
49.

Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research.

Celis JE, Gromov P, Gromova I, Moreira JM, Cabezón T, Ambartsumian N, Grigorian M, Lukanidin E, Thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jäättelä M, Roepstorff P, Bolund L, Ørntoft T, Brünner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE.

Mol Cell Proteomics. 2003 Jun;2(6):369-77. Epub 2003 Jun 25.

50.

Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma.

Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Rønnov-Jessen L.

Am J Pathol. 2003 Feb;162(2):391-402.

Supplemental Content

Support Center